Table 1.
Selection of clinical trials and approved anti-angiogenic therapies in hematological malignancies
| Drug | Target | Study entities | Approved for |
|---|---|---|---|
| Receptor tyrosine kinase inhibitors | |||
| PTK787/ZK 222584 (Vatalanib®) | VEGFR1-3, PDGFRβ, c-Kit | AML, PMF, MDS, CML, DLBCL, MM | |
| SU5416 (Semaxinib) |
VEGFR1-2, c-kit, Flt3 | AML, MDS, MM, MPN | |
| Sorafenib (Nexavar®) | VEGFR2-3, B-Raf, Faf-1, PDGFRβ | AML, ALL, MDS, CML, CLL, NHL, MM | Advanced renal cell carcinoma, HCC |
| Sunitinib (Sutent®) | VEGFR1-3, PDGFRα+β, c-kit, Flt3 | AML, MDS, CLL, Myeloma, NHL | Advanced renal cell carcinoma, GIST |
| PKC-412 (Midostaurin) | VEGFR2, PKC, PDGFR, Flt3, c-Kit | AML | |
| Cediranib (Recentin®) | VEGFR1-3, PDGFRβ, c-Kit | AML, MDS, CLL | |
| Proteasome inhibitors | |||
| Bortezomib (Velcade®) | 26S proteasome, NF-κB | AML, ALL, MDS, CML, NHL, MCL | MM, MCL |
| Anti-VEGF strategies | |||
| Bevacizumab (Avastin®) | VEGF-A | AML, MDS, CLL, CML, NHL, MM | Metastatic colorectal cancer, NSCLC, breast cancer |
| Immunomodulatory drugs | |||
| Thalidomide | bFGF, VEGF, IL-6 | AML, MDS, MPN, CLL, NHL, MM | MM |
| Lenalidomide (Revlimid®) | bFGF, VEGF, IL-6 | AML, MDS, CLL, NHL | MM, 5q- MDS |
AML, acute myeloid leukemia; bFGF, basic fibroblast growth factor; DLBCL, diffuse large B-cell lymphoma; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; GIST, gastrointestinal stromal tumors; HCC, hepatocellular carcinoma; IL-6, Interleukin-6; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasm; PMF, primary myelofibrosis; VEGF, vascular endothelial growth factor.